Cambridge Investment Research Advisors Inc. Purchases Shares of 10,380 Verve Therapeutics, Inc. (NASDAQ:VERV)

Cambridge Investment Research Advisors Inc. acquired a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,380 shares of the company’s stock, valued at approximately $47,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in VERV. BVF Inc. IL boosted its position in shares of Verve Therapeutics by 962.2% during the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock worth $38,939,000 after purchasing an additional 6,254,050 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Verve Therapeutics in the 4th quarter valued at about $7,863,000. Schonfeld Strategic Advisors LLC lifted its position in Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock valued at $21,372,000 after acquiring an additional 1,382,176 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Verve Therapeutics in the 4th quarter valued at about $1,643,000. Finally, Jacobs Levy Equity Management Inc. lifted its position in Verve Therapeutics by 18.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company’s stock valued at $10,423,000 after acquiring an additional 288,678 shares in the last quarter. Institutional investors own 97.11% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on VERV shares. Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. William Blair cut shares of Verve Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Tuesday, June 17th. BMO Capital Markets reissued a “market perform” rating and set a $13.50 target price (down previously from $20.00) on shares of Verve Therapeutics in a research report on Friday, June 27th. Lifesci Capital cut shares of Verve Therapeutics from a “strong-buy” rating to a “hold” rating and set a $12.00 target price on the stock. in a research report on Wednesday, June 18th. Finally, Wall Street Zen raised shares of Verve Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Verve Therapeutics presently has an average rating of “Hold” and an average price target of $14.57.

Verve Therapeutics Trading Down 0.1%

Verve Therapeutics stock opened at $11.02 on Wednesday. Verve Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $11.41. The firm has a market capitalization of $982.32 million, a price-to-earnings ratio of -5.22 and a beta of 2.23. The firm has a 50 day simple moving average of $7.55 and a 200 day simple moving average of $6.54.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.36. The firm had revenue of $32.98 million during the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. On average, equities research analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.